Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals Over FDA Hold on Clinical Trial

Investors who purchased or acquired shares of Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, may be eligible to participate in a securities class action lawsuit after the FDA placed a clinical hold on the company's Phase 2 pivotal trial for RP-A501, an experimental therapy for Danon disease. The lawsuit seeks to represent investors who suffered losses as a result of the company's announcement on May 27, 2025, which caused a 60% drop in the price of Rocket Pharmaceuticals shares. Hagens Berman is urging investors to submit their losses and is also seeking individuals with knowledge that may aid in the investigation.

Key Takeaways:

• The lawsuit aims to represent investors who purchased or acquired Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025.
• The company's announcement on May 27, 2025, regarding the FDA's clinical hold on the Phase 2 pivotal trial for RP-A501 led to a 60% drop in share price.
• The lawsuit alleges that Rocket Pharmaceuticals failed to disclose material information regarding the clinical hold, leading to investor losses.
• The class period for affected investors spans from February 27, 2025, to May 26, 2025.
• The lead plaintiff deadline for the lawsuit is August 11, 2025.
• Individuals with knowledge related to the case are encouraged to contact Hagens Berman's attorneys.

Statistics:

• 60%: The percentage drop in share price of Rocket Pharmaceuticals on May 27, 2025.
• February 27, 2025: The starting date of the class period for affected investors.
• May 26, 2025: The end date of the class period for affected investors.
• August 11, 2025: The lead plaintiff deadline for the lawsuit.

Sources:

• Phamaceutical Law Weekly, June 24, 2025.
• Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.).